Showing results (41-50 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification ConsortiumBartolome Celli, Kay Tetzlaff, Gerard Criner, et al.
Advances in Therapy|October 6, 2025
The Global Patient Perspective on Uncontrolled Moderate-to-Severe Asthma: Reducing Delays in Diagnosis and TreatmentKaren Rance, Brenda Young, Gretchen McCreary, et al.
Chest|February 3, 2016
Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints CohortAbebaw M Yohannes, Hana Müllerová, Nicola A Hanania, et al.
BMC Pharmacology & Toxicology|June 21, 2015
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjectsBruce E Miller, Sunil Mistry, Kevin Smart, et al.
ERJ Open Research|April 27, 2019
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patientsSofie Lock Johansson, Helle Wulf-Johansson, Anders Schlosser, et al.
The European Respiratory Journal|December 21, 2011
Metabolic profiling detects biomarkers of protein degradation in COPD patientsBaljit K Ubhi, John H Riley, Paul A Shaw, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD PatientsPaul W Jones, Heather Gelhorn, Niklas Karlsson, et al.
ERJ Open Research|December 2, 2020
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixinHolly R Keir, Hollian Richardson, Christina Fillmore, et al.
American Journal of Respiratory and Critical Care Medicine|July 2, 2015
Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lungJohn G Yonchuk, Edwin K Silverman, Russell P Bowler, et al.
Environmental Health Perspectives|June 19, 2008
Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteersNeil E Alexis, John C Lay, Angela Haczku, et al.
Pageof 21